|
시장보고서
상품코드
2081452
항암제 시장 : 약제 클래스별, 투여 경로, 분자 유형, 적응증, 최종 사용자, 유통 채널별 - 세계 예측(2026-2032년)Oncology Drugs Market by Drug Class, Route of Administration, Molecule Type, Indication, End User, Distribution Channel - Global Forecast 2026-2032 |
||||||
360iResearch
항암제 시장은 2032년까지 연평균 복합 성장률(CAGR) 7.55%로 성장해 3,761억 달러 규모로 확대될 것으로 예측됩니다.
| 주요 시장 통계 | |
|---|---|
| 기준 연도(2025년) | 2,258억 6,000만 달러 |
| 추정 연도(2026년) | 2,423억 2,000만 달러 |
| 예측 연도(2032년) | 3,761억 달러 |
| CAGR(%) | 7.55% |
암 발병률 증가, 정밀 의학, 그리고 면역종양학, 표적 치료, 항체-약물 복합체, 방사성 의약품, 세포 및 유전자 치료의 급속한 확산에 힘입어 항암제 시장은 재편되고 있습니다. 국제암연구소(IARC)의 'GLOBOCAN 2022' 추산에 따르면, 전 세계적으로 약 2,000만 명의 신규 암 환자와 970만 명의 암 사망자가 확인되었으며, 이는 효과적인 항암제에 대한 임상적 수요가 여전히 높음을 보여줍니다.
수요는 생존율 향상, 독성 감소, 그리고 분자진단을 바탕으로 한 치료의 실현으로 이어지는 치료법에 점점 더 집중되고 있습니다. 미국 식품의약국(FDA) 및 유럽의약품청(EMA)의 승인 현황을 보면, 바이오마커에 기반한 적응증, 종양 유형에 구애받지 않는 치료법, 그리고 미충족 의료 수요가 높은 중증 암에 대한 신속 승인 절차의 추세가 지속되고 있음을 알 수 있습니다. 업계 리더에게 있어 경쟁 우위는 이제 증거 창출, 동반 진단, 접근 전략, 제조 탄력성, 그리고 전 세계 종양 치료 현장에서의 라이프사이클 관리에 달려 있습니다.
종양학 의약품 분야의 혁신적인 변화
암 치료의 양상은 광범위한 세포독성 요법에서 보다 개인 맞춤형 병용 요법을 기반으로 한 치료 모델로 전환되고 있습니다. 면역관문억제제, 키나아제 억제제, PARP 억제제, 이중 특이성 항체, CAR-T 세포 치료, 항체-약물 복합체 및 방사성 리간드 치료가 혈액 악성 종양과 고형암에 걸친 치료 선택지를 확대되고 있습니다.
항암제 분야에서 인공지능이 미친 누적 영향
인공지능은 항암제 신약 개발, 임상 개발, 메디컬 어페어즈, 그리고 상용화에 이르는 모든 영역에 걸쳐 누적 영향을 미치고 있습니다. AI를 활용한 모델은 유전체 데이터, 병리 영상, 방사선 영상, 전자 진료 기록 및 임상시험 데이터 세트의 분석에 활용되며, 표적 식별, 환자 계층화, 치료 반응 예측 및 임상시험의 실현 가능성 향상에 기여하고 있습니다.
항암제 시장의 주요 지역별 분석
북미는 선진적인 임상시험 인프라, 바이오마커 검사의 높은 보급률, 막대한 생의학 연구 투자, 그리고 중증 질환에 대한 신속한 개발을 지원하는 미국의 규제 프로그램에 힘입어, 계속해서 항암제 혁신의 중심지로서의 위상을 유지하고 있습니다. 미국은 새로운 면역요법, 표적 치료법 및 첨단 세포 치료법이 널리 이용 가능하기 때문에 지역 전체 수요를 주도하고 있습니다. 한편, 캐나다에서는 의료 기술 평가, 캐나다 전역을 대상으로 하는 심사 절차, 그리고 접근 시기를 좌우하는 각 주의 보상 체계가 중시되고 있습니다.
항암제 전략에 관한 주요 그룹별 인사이트
아세안(ASEAN) 지역 내에서는 암 검진, 전문 병원, 병리 검사 역량 및 각국의 보험 급여 제도 확대에 따라 항암제 수요가 증가하고 있지만, 고소득 회원국과 중저소득 회원국 간에는 여전히 접근성에 격차가 존재합니다. 보편적 의료 보장(UHC)과 3차 암 의료 네트워크가 잘 갖춰진 국가들은 바이오마커 기반 치료법을 도입할 준비가 되어 있는 반면, 기타 국가들은 여전히 필수 항암제 확보, 진단 역량 확충, 그리고 합리적인 가격 확보를 우선시하고 있습니다. GCC 국가들은 암 센터, 유전체 검사, 전문 병원 네트워크 및 국가 암 전략에 투자하여 혁신적인 항암제에 대한 수요를 창출하는 한편, 조달 효율성, 현지 의료 시스템의 우선순위 및 인재 양성을 중시하고 있습니다.
항암제에 관한 주요 국가의 동향
미국은 활발한 임상시험 활동, 규제 당국의 빈번한 항암제 승인, 학술적 암 센터, 첨단 분자 검사, 그리고 적격 환자 집단을 대상으로 한 면역요법, 표적 치료, 세포 치료의 광범위한 활용을 통해 전 세계 항암제 상용화를 주도하고 있습니다. 캐나다는 국가 및 주 차원의 심사 체계를 통해 증거에 기반한 보험 급여를 우선시하고 있습니다. 한편, 멕시코와 브라질은 공공 부문의 접근성, 민간 보험의 적용 범위, 확대되는 암 의료 네트워크, 그리고 적시 진단 및 바이오마커 검사 분야에서 여전히 존재하는 격차에 의해 형성된 라틴아메리카의 주요 기회를 상징하고 있습니다.
암 치료 업계의 리더을 위한 실천적인 제안
업계 리더는 임상시험 설계, 동반 진단, 규제 당국에 대한 신청, 그리고 시장 진입과 관련된 근거를 초기 단계부터 연계하는 바이오마커 주도형 개발 계획을 우선시해야 합니다. 항암제 포트폴리오는 종양의 유형뿐만 아니라, 작용기전, 내성 메커니즘, 치료 순차 적용 가능성, 내약성, 병용 전략, 그리고 명확하게 정의된 미충족 의료 수요에 대응할 수 있는 능력에 의해서도 평가되어야 합니다.
항암제 시장 분석을 위한 조사 방법
본 요약본은 세계보건기구(WHO), 국제암연구소(IARC)의 GLOBOCAN 데이터베이스, 미국 식품의약국(FDA), 유럽의약품청(EMA), 각국의 암 대책 기관, 동료 심사를 거친 암 관련 문헌, 임상시험 등록부, 치료 지침, 그리고 공개된 규제 문서 등 신뢰성이 높은 공개 정보원을 바탕으로 한 2차 조사를 통해 작성되었습니다. 본 분석에서는 질병 부담, 규제 동향, 치료법의 혁신, 지역별 접근성 동향, 진단 체계의 구축 현황, 그리고 의료 인프라 지표에 대해 평가했습니다.
결론 : 항암제의 전략적 전망
항암제 시장은 더욱 정밀하고, 데이터 집약적이며, 접근성에 민감한 단계에 접어들었습니다. 과학의 발전에 따라 면역요법, 표적요법, 항체-약물 복합체, 방사성 의약품, 세포요법 등 치료 선택지가 확대되고 있지만, 성공 여부는 차별화된 임상적 가치의 입증, 진단 수단의 정비, 그리고 다양한 의료 시스템 전반에 걸친 적시 공급 확보에 달려 있다는 점이 점점 더 뚜렷해지고 있습니다.
자주 묻는 질문
목차
제1장 서문
제2장 조사 방법
제3장 주요 요약
제4장 시장 개요
제5장 시장 인사이트
제6장 AI의 누적 영향(2026년)
제7장 항암제 시장 : 약제 클래스별
제8장 항암제 시장 : 투여 경로별
제9장 항암제 시장 : 분자 유형별
제10장 항암제 시장 : 적응증별
제11장 항암제 시장 : 최종 사용자별
제12장 항암제 시장 : 유통 채널별
제13장 항암제 시장 : 지역별
제14장 항암제 시장 : 그룹별
제15장 항암제 시장 : 국가별
제16장 경쟁 구도
제17장 기업 개요
KTH 26.07.13The Oncology Drugs Market is projected to grow by USD 376.10 billion at a CAGR of 7.55% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 225.86 billion |
| Estimated Year [2026] | USD 242.32 billion |
| Forecast Year [2032] | USD 376.10 billion |
| CAGR (%) | 7.55% |
The oncology drugs market is being reshaped by rising cancer incidence, precision medicine, and the rapid expansion of immuno-oncology, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell and gene therapies. According to the International Agency for Research on Cancer's GLOBOCAN 2022 estimates, there were approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the sustained clinical need for effective cancer therapeutics.
Demand is increasingly concentrated around therapies that improve survival, reduce toxicity, and align treatment with molecular diagnostics. Regulatory approvals from the U.S. Food and Drug Administration and the European Medicines Agency show continued momentum for biomarker-directed indications, tumor-agnostic therapies, and expedited pathways for serious cancers with unmet need. For industry leaders, competitive advantage now depends on evidence generation, companion diagnostics, access strategy, manufacturing resilience, and lifecycle management across global oncology care settings.
Transformative Shifts in the Oncology Drugs Landscape
The oncology therapeutics landscape is moving from broad cytotoxic regimens toward more personalized, combination-based treatment models. Immune checkpoint inhibitors, kinase inhibitors, PARP inhibitors, bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates, and radioligand therapies are expanding treatment options across hematologic malignancies and solid tumors.
A major transformative shift is the integration of diagnostics into drug development and clinical decision-making. Biomarkers such as PD-L1, MSI-H/dMMR, EGFR, ALK, HER2, BRCA, BRAF, NTRK, and KRAS G12C increasingly determine eligibility, sequencing, and expected response. At the same time, payers and health systems are demanding real-world evidence, comparative effectiveness data, patient-reported outcomes, and outcomes-based value narratives as oncology drug costs rise and treatment pathways become more complex.
Cumulative Impact of Artificial Intelligence in Oncology Drugs
Artificial intelligence is having a cumulative impact across oncology drug discovery, clinical development, medical affairs, and commercialization. AI-enabled models are used to analyze genomics, pathology images, radiology scans, electronic health records, and clinical trial datasets to identify targets, stratify patients, predict response, and improve trial feasibility.
The strongest near-term value is emerging in patient matching, adaptive trial design, pharmacovigilance signal detection, biomarker discovery, synthetic control arm development, and evidence synthesis from real-world datasets. However, adoption depends on validated datasets, transparent model governance, regulatory alignment, cybersecurity safeguards, bias mitigation, and clinical usability. In oncology, where treatment decisions can be life-critical, AI must augment expert judgment rather than replace evidence-based medical practice.
Key Regional Insights Across Oncology Drug Markets
North America remains a central hub for oncology drug innovation, supported by advanced clinical trial infrastructure, high biomarker testing adoption, substantial biomedical research investment, and U.S. regulatory programs that support expedited development for serious diseases. The United States anchors regional demand through broad availability of novel immunotherapies, targeted therapies, and advanced cellular therapies, while Canada emphasizes health technology assessment, pan-Canadian review processes, and provincial reimbursement pathways that shape access timelines.
Europe combines strong scientific capabilities with a structured regulatory and reimbursement environment shaped by the European Medicines Agency, national health technology assessment bodies, and cross-border cancer policy initiatives. The region's oncology drug landscape is influenced by centralized medicine evaluation, national pricing negotiations, and growing emphasis on equitable cancer care under European cancer policy frameworks. Asia-Pacific is gaining importance through China's expanding biopharmaceutical sector, Japan's mature oncology treatment environment, South Korea's clinical research ecosystem, India's high patient volumes and biosimilar capabilities, and Australia's advanced regulatory and trial capabilities.
Latin America presents meaningful unmet need, with Brazil and Mexico serving as key access and commercialization markets, although reimbursement variability, out-of-pocket burden, and diagnostic infrastructure gaps remain important constraints. The Middle East is increasing investment in oncology centers, genomic medicine, and specialty care, particularly in Gulf countries where national health transformation programs are strengthening cancer services. Africa faces the largest access challenges, including late diagnosis, limited oncology workforce, constrained pathology and radiotherapy capacity, and restricted availability of advanced therapies, making affordability, early detection, and essential cancer medicines critical priorities.
Key Group Insights for Oncology Drug Strategy
Within ASEAN, oncology drug demand is increasing as cancer screening, specialty hospitals, pathology capacity, and national reimbursement schemes expand, but access remains uneven across high-income and lower-middle-income member states. Countries with stronger universal health coverage and tertiary cancer networks are better positioned to adopt biomarker-driven therapies, while others continue to prioritize essential cancer medicines, diagnostic scale-up, and affordability. The GCC is investing in cancer centers, genomic testing, specialty hospital networks, and national cancer strategies, creating demand for innovative oncology drugs while emphasizing procurement efficiency, local health system priorities, and workforce development.
The European Union remains influential through centralized medicine evaluation, pharmacovigilance standards, joint clinical assessment under evolving health technology assessment rules, and policy initiatives tied to Europe's Beating Cancer Plan. These mechanisms are reinforcing evidence expectations for oncology drugs, including comparative clinical benefit, quality-of-life outcomes, and real-world effectiveness. BRICS markets are strategically important because they combine large patient populations, growing domestic manufacturing capacity, expanding biosimilar use, and increasing participation in global oncology trials, although affordability, regional access variation, and reimbursement complexity differ widely across member countries.
G7 countries remain the most commercially significant group for premium oncology innovation due to mature reimbursement systems, strong academic oncology networks, advanced clinical trial infrastructure, and high adoption of biomarker-driven care. NATO countries overlap heavily with advanced North American and European markets, where medicine security, resilient supply chains, cybersecurity, and protection of critical health infrastructure are becoming increasingly relevant to oncology drug availability, especially for biologics, radiopharmaceuticals, and complex personalized therapies.
Key Country Insights in Oncology Drugs
The United States leads global oncology commercialization through high clinical trial activity, frequent oncology regulatory approvals, academic cancer centers, advanced molecular testing, and broad use of immunotherapy, targeted therapy, and cellular therapy in eligible populations. Canada prioritizes evidence-based reimbursement through national and provincial review structures, while Mexico and Brazil represent major Latin American opportunities shaped by public-sector access, private insurance coverage, expanding oncology networks, and persistent disparities in timely diagnosis and biomarker testing.
In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology expertise with national reimbursement assessment and established specialist care pathways, while Germany's early access and benefit assessment pathway remains especially important for launch planning. The United Kingdom continues to emphasize health technology assessment and managed access mechanisms, France applies structured clinical benefit evaluation, and Italy and Spain balance national assessment with regional implementation. Russia remains a complex oncology market influenced by localization requirements, procurement structures, regulatory considerations, and geopolitical constraints that affect access and supply continuity.
China has become a major force in oncology research and development, clinical trials, and domestic biologics innovation, supported by regulatory reforms, expanding hospital capacity, and rising use of targeted therapies and immuno-oncology in specialist centers. India offers large patient volumes, deep generic and biosimilar manufacturing capabilities, and growing oncology service capacity, though affordability and uneven diagnostic access remain central. Japan maintains strong uptake of innovative oncology drugs under a mature regulatory and reimbursement system, South Korea is a leading clinical research and biopharma innovation hub with advanced hospital networks, and Australia supports high-quality trials, genomic medicine initiatives, and early adoption through robust regulatory oversight.
Actionable Recommendations for Oncology Industry Leaders
Industry leaders should prioritize biomarker-driven development plans that connect clinical trial design, companion diagnostics, regulatory submissions, and market access evidence from the earliest stages. Oncology drug portfolios should be evaluated not only by tumor type but also by mechanism of action, resistance biology, sequencing potential, tolerability, combination strategy, and ability to address clearly defined unmet need.
Organizations should strengthen real-world evidence capabilities, diversify clinical trial recruitment, and build access models that address affordability across mature and emerging markets. Supply chain resilience is essential for biologics, radiopharmaceuticals, and cell therapies, where cold chain reliability, isotope availability, manufacturing slots, quality systems, and site certification can directly affect patient access. Leaders should also align medical education, diagnostic partnerships, and value communication to ensure that eligible patients can be identified and treated appropriately.
Research Methodology for Oncology Drug Market Analysis
This executive summary is built on secondary research from validated public sources, including the World Health Organization, the International Agency for Research on Cancer's GLOBOCAN database, the U.S. Food and Drug Administration, the European Medicines Agency, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, treatment guidelines, and public regulatory documents. The analysis evaluates disease burden, regulatory trends, therapeutic innovation, regional access dynamics, diagnostic readiness, and healthcare infrastructure indicators.
Insights were synthesized using a structured market intelligence framework that compares clinical evidence, treatment pathways, approval activity, reimbursement considerations, biomarker adoption, manufacturing requirements, and geographic adoption patterns. Emphasis was placed on verifiable information and directional conclusions supported by recognized oncology data sources rather than speculative projections, market sizing, or forecasting.
Conclusion: Strategic Outlook for Oncology Drugs
The oncology drugs market is entering a more precise, data-intensive, and access-sensitive phase. Scientific progress is expanding treatment options across immunotherapy, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell-based therapies, but success increasingly depends on proving differentiated clinical value, enabling diagnostics, and ensuring timely availability across diverse healthcare systems.
Organizations that combine strong research productivity with biomarker strategy, AI-enabled evidence generation, regulatory discipline, manufacturing reliability, and equitable access planning will be best positioned to lead in the next phase of oncology therapeutics.
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Definition
- 1.3. Market Segmentation & Coverage
- 1.4. Years Considered for the Study
- 1.5. Currency Considered for the Study
- 1.6. Language Considered for the Study
- 1.7. Key Stakeholders
2. Research Methodology
- 2.1. Introduction
- 2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
- 2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
- 2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
- 2.5. Data Triangulation
- 2.6. Research Outcomes
- 2.7. Research Assumptions
- 2.8. Research Limitations
3. Executive Summary
- 3.1. Introduction
- 3.2. CXO Perspective
- 3.3. Market Size & Growth Trends
- 3.4. Market Share Analysis, 2025
- 3.5. FPNV Positioning Matrix, 2025
- 3.6. New Revenue Opportunities
- 3.7. Next-Generation Business Models
- 3.8. Industry Roadmap
4. Market Overview
- 4.1. Introduction
- 4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
- 4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
- 4.4. Porter's Five Forces Analysis
- 4.5. PESTLE Analysis
- 4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
- 4.7. Go-to-Market Strategy
5. Market Insights
- 5.1. Consumer Insights & End-User Perspective
- 5.2. Consumer Experience Benchmarking
- 5.3. Opportunity Mapping
- 5.4. Distribution Channel Analysis
- 5.5. Pricing Trend Analysis
- 5.6. Regulatory Compliance & Standards Framework
- 5.7. ESG & Sustainability Analysis
- 5.8. Disruption & Risk Scenarios
- 5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncology Drugs Market, by Drug Class
- 7.1. Chemotherapy Agents
- 7.1.1. Alkylating Agents
- 7.1.2. Antimetabolites
- 7.2. Hormonal Therapy Agents
- 7.3. Immunotherapy Agents
- 7.3.1. CAR T-Cell Therapy
- 7.3.2. Checkpoint Inhibitors
- 7.3.2.1. CTLA-4 Inhibitors
- 7.3.2.2. PD-1/PD-L1 Inhibitors
- 7.4. Targeted Therapy Agents
- 7.4.1. Monoclonal Antibodies
- 7.4.1.1. Chimeric
- 7.4.1.2. Humanized
- 7.4.2. Small Molecule Inhibitors
- 7.4.2.1. Cyclin-Dependent Kinase Inhibitors
- 7.4.2.2. Tyrosine Kinase Inhibitors
- 7.4.1. Monoclonal Antibodies
8. Oncology Drugs Market, by Route of Administration
- 8.1. Injectable
- 8.1.1. Intramuscular
- 8.1.2. Intravenous
- 8.1.3. Subcutaneous
- 8.2. Oral
9. Oncology Drugs Market, by Molecule Type
- 9.1. Biologics
- 9.1.1. Monoclonal Antibodies
- 9.1.2. Vaccines
- 9.2. Small Molecules
10. Oncology Drugs Market, by Indication
- 10.1. Blood Cancer
- 10.1.1. Leukemia
- 10.1.1.1. Acute Myeloid Leukemia
- 10.1.1.2. Chronic Lymphocytic Leukemia
- 10.1.2. Lymphoma
- 10.1.2.1. Hodgkin Lymphoma
- 10.1.2.2. Non-Hodgkin Lymphoma
- 10.1.1. Leukemia
- 10.2. Breast Cancer
- 10.3. Colorectal Cancer
- 10.4. Lung Cancer
- 10.5. Prostate Cancer
11. Oncology Drugs Market, by End User
- 11.1. Hospitals
- 11.2. Research Institutes
- 11.3. Specialty Clinics
12. Oncology Drugs Market, by Distribution Channel
- 12.1. Hospital Pharmacies
- 12.2. Online Pharmacies
- 12.3. Retail Pharmacies
13. Oncology Drugs Market, by Region
- 13.1. Asia-Pacific
- 13.2. North America
- 13.3. Latin America
- 13.4. Europe
- 13.5. Middle East
- 13.6. Africa
14. Oncology Drugs Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
15. Oncology Drugs Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
16. Competitive Landscape
- 16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
- 16.2. Recent Developments & Impact Analysis, 2025
- 16.3. Product Portfolio Analysis, 2025
- 16.4. Benchmarking Analysis, 2025
17. Company Profiles
- 17.1. Abbott Ltd.
- 17.2. AbbVie Inc.
- 17.3. Agenus Inc.
- 17.4. Amgen Inc.
- 17.5. Apres-demain SA
- 17.6. Aspen Pharmacare Holdings Limited
- 17.7. Astellas Pharma Inc.
- 17.8. AstraZeneca PLC
- 17.9. Bayer AG
- 17.10. BeiGene, Inc.
- 17.11. Biovista Inc.
- 17.12. Blueprint Medicines Corporation
- 17.13. Bristol-Myers Squibb Company
- 17.14. C.H. Boehringer Sohn AG & Co. KG
- 17.15. Cellectar Biosciences, Inc.
- 17.16. Cipla Limited
- 17.17. Dr Reddy's Laboratories Ltd.
- 17.18. Eisai Co., Ltd.
- 17.19. Eli Lilly and Company
- 17.20. Exelixis, Inc.
- 17.21. F. Hofmann-La Roche Ltd.
- 17.22. Genentech, Inc
- 17.23. GlaxoSmithKline PLC
- 17.24. Glenmark Pharmaceuticals Ltd.
- 17.25. Hetero Healthcare Limited
- 17.26. Ipsen SA
- 17.27. Janssen Pharmaceuticals, Inc.
- 17.28. Johnson & Johnson Services, Inc.
- 17.29. Lupin Limited
- 17.30. Merck & Co., Inc.
- 17.31. Merck KGaA
- 17.32. MSN Laboratories
- 17.33. Natco Pharma Ltd.
- 17.34. Novartis AG
- 17.35. Pfizer Inc.
- 17.36. Puma Biotechnology, Inc.
- 17.37. Sanofi S.A.
- 17.38. Sun Pharmaceutical Industries Ltd
- 17.39. Sutro Biopharma, Inc.
- 17.40. Takeda Pharmaceutical Company Limited
- 17.41. Teva Pharmaceutical Industries Ltd
- 17.42. Vascular Biogenics Ltd.
- 17.43. Viatris Inc.
